SLNO Stock Cash Flow Statements

Soleno Therapeutics Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Soleno Therapeutics Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31

cash flows from operating activities:
net income	-4,708,000	-43,773,000	-55,982,000	-76,616,000	-21,854,000	-21,398,000	-11,296,000	-10,861,000	-8,475,000	-8,356,000	-5,486,000	-6,132,000	-6,725,000	-5,724,000	-2,828,000	-8,140,000	-10,988,000	-8,954,000	-2,852,000	-8,545,000	-7,384,000	-5,858,000	-14,625,000	889,000	-10,008,000	-7,030,000	263,000	-2,206,000	-7,637,000	-3,755,000	-5,025,425	-3,786,000	-3,969,000	-2,887,000	-2,613,214	-2,750,000	-3,513,000	-3,189,000	-2,844,546	-3,294,000	1,881,000	-11,651,000	-7,855,513
adjustments to reconcile net income to net cash from operating activities:
depreciation and amortization	502,000	504,000	503,000	500,000	494,000	490,000	489,000	490,000	489,000	490,000	488,000	492,000	492,000	492,000	492,000	492,000	490,000	489,000	488,000	489,000	488,000	489,000	490,000	490,000	489,000	489,000	490,000	490,000	491,000	492,000	582,271	459,000	419,000	151,000	37,640	39,000	35,000	20,000	60,228	17,000	16,000	15,000	8,516
accretion of premium/discount on marketable securities	-974,000	-980,000	-1,400,000	-1,909,000
non-cash lease expense	169,000	195,000		111,000	70,000	69,000		67,000	109,000	78,000		73,000	71,000	71,000		69,000	75,000	76,000
amortization of debt issuance costs	9,000	8,000
stock-based compensation expense	9,698,000	14,679,000	29,755,000	56,598,000	7,160,000	6,445,000	1,909,000	2,201,000	1,204,000	631,000	632,000	683,000	571,000	644,000	418,000	906,000	857,000	1,095,000	393,000	374,000	341,000	392,000	295,000	153,000	175,000	202,000	257,000	211,000	179,000	341,000	25,031	227,000	443,000	185,000	311,270	206,000	218,000	136,000	196,369	144,000	201,000	401,000	324,435
change in fair value of contingent consideration	1,101,000	2,967,000	327,000	877,000	1,637,000	401,000	1,081,000	1,021,000	313,000	299,000	-602,000	132,000	616,000	-858,000	-3,329,000	551,000	3,034,000	-987,000	140,000	774,000	2,842,000	584,000	-128,000	28,000	183,000	206,000	-22,000	228,000	-67,000	428,000				5,000		8,000	8,000	19,000
other non-cash reconciling items	12,000	4,000		-1,000	-1,000	-1,000				16,000		-1,000	1,000	-2,000
change in operating assets and liabilities:
accounts receivable																																		23,000	3,790	151,000	-101,000	-31,000	-62,127	-82,000	-4,000	-8,000	37,605
inventory																																	32,000	-195,000	42,617	71,000	-121,000	-102,000
prepaid expenses, other current assets and other assets	3,077,000	-3,416,000	-1,029,000	-101,000	299,000	81,000	-660,000	113,000	44,000	-334,000	-224,000	3,000	220,000	114,000			-15,000	98,000	-671,000	157,000	126,000	-161,000
accounts payable	733,000	-3,336,000	2,578,000	2,527,000	-4,298,000	4,865,000	34,000	-341,000	678,000	1,001,000	-547,000	-82,000	198,000	-1,046,000	-604,000	522,000	-1,333,000	1,180,000	279,000	-404,000	134,000	1,485,000	260,000	-5,000	482,000	324,000	-363,000	264,000	-61,000	409,000	-41,370	-38,000	445,000	-175,000	-324,163	-159,000	-293,000	627,000	-330,055	141,000	202,000	199,000	250,897
accrued compensation	1,990,000	-499,000	1,368,000	1,259,000	923,000	-1,909,000	1,637,000	333,000	444,000	-954,000	393,000	350,000	334,000	-130,000	-81,000	157,000	241,000	-594,000	249,000	236,000	182,000	55,000
accrued clinical trial site costs	39,000	-2,000	64,000	-101,000	-532,000	-998,000	156,000	-229,000	-65,000	309,000	396,000	-330,000	-365,000	101,000	-173,000	-334,000	-213,000	351,000	390,000	-45,000	598,000	847,000
operating lease liabilities	-34,000	-40,000	-31,000	-45,000	-51,000	-56,000	-67,000	-15,000	-111,000	-116,000	-84,000	-98,000	-86,000	-34,000	-107,000	12,000	-86,000	-82,000	-81,000	-217,000	-17,000	10,000
other liabilities	2,497,000	937,000	-341,000	1,975,000	-385,000	-44,000	805,000	237,000	-179,000	208,000	-187,000	256,000	55,000	37,000	-164,000	237,000	21,000	41,000	-170,000	255,000	-105,000	-157,000
net cash from operating activities	-12,608,000	-32,752,000	-23,991,000	-14,926,000	-17,651,000	-12,528,000	-6,314,000	-6,332,000	-5,566,000	-6,728,000	-5,143,000	-4,656,000	-4,620,000	-6,362,000	-6,863,000	-5,406,000	-8,013,000	-7,488,000	-6,867,000	-6,164,000	-6,534,000	-5,659,000	-5,076,000	-4,719,000	-3,893,000	-3,687,000	-3,736,000	-2,677,000	-2,750,000	-2,520,000	-2,731,958	-2,271,000	-2,764,000	-2,183,000	-2,687,980	-2,786,000	-4,040,000	-3,984,000	-3,378,330	-2,861,000	-2,251,000	-1,809,000	-1,556,362
capex	-9,000	-5,000	-8,000	-191,000	-8,000	-3,000	0	0	0	0	-6,000	0	0	0	-13,000	-5,000	0	-4,000	-6,000	0	0	0	-5,000	0	-6,000	-10,000	-2,000	-5,000	0	0	1,431	0	0	-4,000	320	0	-20,000	-19,000	-7,777	-32,000	-15,000	-1,000	0
free cash flows	-12,617,000	-32,757,000	-23,999,000	-15,117,000	-17,659,000	-12,531,000	-6,314,000	-6,332,000	-5,566,000	-6,728,000	-5,149,000	-4,656,000	-4,620,000	-6,362,000	-6,876,000	-5,411,000	-8,013,000	-7,492,000	-6,873,000	-6,164,000	-6,534,000	-5,659,000	-5,081,000	-4,719,000	-3,899,000	-3,697,000	-3,738,000	-2,682,000	-2,750,000	-2,520,000	-2,730,527	-2,271,000	-2,764,000	-2,187,000	-2,687,660	-2,786,000	-4,060,000	-4,003,000	-3,386,107	-2,893,000	-2,266,000	-1,810,000	-1,556,362
cash flows from investing activities:
purchases of property and equipment	-9,000	-5,000	-8,000	-191,000	-8,000	-11,000					-6,000	0			-13,000	-5,000	0	-4,000	-4,000				-5,000	0	-6,000	-10,000	-2,000	-5,000
purchases of marketable securities	-59,406,000	-45,358,000	-47,549,000	-47,769,000	-145,913,000	-115,233,000
maturities of marketable securities	51,500,000	68,300,000	54,000,000	52,000,000
net cash from investing activities	-7,915,000	22,937,000	6,443,000	4,040,000	-120,921,000	-115,244,000					-6,000	0			-13,000	-5,000	0	-4,000	-4,000				103,000	441,000	-6,000	-10,000					239,782	371,000	-228,000	-4,000	320	0	-20,000	-19,000	-31,777	-1,258,000	-30,000	-1,000
cash flows from financing activities:
payment of debt issuance costs	0	-62,000
payment of deferred financing costs
proceeds from the sale of common stock, net of issuance costs			0	0
proceeds from exercise of common stock warrants	2,176,000	3,011,000				923,000
proceeds from exercise of common stock and pre-funded stock warrants
proceeds received prior to and for the issuance of common stock and pre-funded warrants
proceeds from exercise of stock options	13,724,000	269,000	-1,000	765,000	537,000	15,000
tax withholding payments for net share-settled equity awards											0	0	0	-16,000	0	0	0	-120,000
net cash from financing activities	15,689,000	3,218,000	57,063,000	2,275,000	152,749,000	938,000	123,558,000	39,401,000			0	342,000	-282,000	14,032,000	-5,000	0	2,000	-125,000	-42,000	-195,000	53,963,000	-4,000					16,302,000	700,000	537,000	288,000	13,944,687	0	0	10,000,000	-867	5,699,000	70,000	5,000,000	4,184,920	1,309,000	282,000	3,382,000	9,479,985
net decrease in cash and cash equivalents	-4,834,000	-6,597,000				-126,834,000					-5,149,000							-7,617,000				-5,663,000													-2,688,527	2,913,000
cash and cash equivalents, beginning of period	0	87,928,000	0	0	0	169,681,000	0	0	0	14,602,000	0	0	0	21,304,000	0	0	0	49,224,000	0	0	0	20,733,000									-4	0	0	2,726,000	-477	0	0	5,495,000	-290	0	0	7,957,000	-230
cash and cash equivalents, end of period	-4,834,000	81,331,000	39,515,000	-8,611,000	14,177,000	42,847,000	117,244,000	33,069,000	11,494,000	7,874,000	-5,149,000	-4,314,000	-4,909,000	28,974,000	-6,881,000	-5,411,000	-8,011,000	41,607,000	-6,913,000	-6,362,000	47,429,000	15,070,000									11,452,507	-1,900,000	-2,992,000	10,539,000	-2,689,004	2,913,000	-3,990,000	6,492,000	774,523	-2,810,000	-1,999,000	9,529,000	7,892,710
supplemental disclosure of non-cash operating and financing information
cash paid for interest	1,255,000	805,000
cash flows from investing activities
purchases of property and equipment included in accounts payable						8,000
noncash lease expense																			73,000	73,000	69,000	68,000
change in fair value of stock warrants								653,000				-2,000	-2,000	-27,000	-139,000	-112,000	-56,000	-201,000	-5,105,000	689,000	-3,808,000	-3,413,000	7,894,000	-7,116,000	4,267,000	1,919,000	-2,071,000	-2,073,000	3,834,000	-212,000
proceeds from issuance of debt, net of issuance costs
proceeds from the sale of common stock, common stock warrants and pre-funded stock warrants, net of issuance costs
net increase in cash and cash equivalents			39,515,000	-8,611,000			117,244,000	33,069,000	11,494,000	-6,728,000			-4,909,000	7,670,000	-6,881,000	-5,411,000			-6,913,000	-6,362,000												-1,900,000	-2,992,000	7,813,000				997,000	774,813	-2,810,000	-1,999,000	1,572,000
operating lease right-of-use assets obtained in exchange for operating lease obligations			0				0	0
non-cash exercise of 2018 pipe warrants
debt issuance costs included in accounts payable
proceeds from the sale of common stock and common stock warrants, net of costs
proceeds from exercise of common stock warrants and pre-funded common stock warrants, net of costs
unpaid financing costs included in accounts payable and accrued liabilities
proceeds received prior to and for the issuance of common stock
supplemental disclosure of non-cash financing information
unpaid financing costs included in accounts payable
accretion of premium/discount on investments						-473,000
change in fair value of common stock warrants																																-130,000	90,000	69,000		-200,000	47,000	-1,170,000		-72,000	-4,925,000	6,174,000
proceeds from sale of common stock, common stock warrants and pre-funded stock warrants, net of issuance costs
proceeds from exercise of common stock warrants and pre-funded stock warrants, net of costs
proceeds from stock option exercises							337,000												0	0
supplemental disclosure of non-cash investing and financing information
proceeds from sale of common stock and common stock warrants, net of issuance costs
proceeds from sale of common stock and pre-funded warrants, net of costs												342,000	-282,000	14,048,000
proceeds from exercise of common stock warrants, net of costs
proceeds from sale of common stock and common stock warrants, net of costs
unpaid costs for issuing common stock and pre-funded warrants														282,000
gross proceeds from sale of common stock and common stock warrants
payment of issuance costs
principal paid on finance lease liabilities															-5,000	0	2,000	-5,000	-4,000	-5,000	-4,000	-4,000
right-of use assets obtained in exchange for operating lease obligations
other assets
supplemental disclosure of non-cash activities
right-of-use assets obtained in exchange for operating lease obligations																0
deferred financing costs included in accounts payable
purchases of property and equipment in accounts payable																			-2,000
prepaid expenses and other current assets																								96,000	132,000	-74,000		47,000	175,000	-80,000
other long-term assets																																			810
proceeds from sale of common stock, net of costs																				-190,000
purchase of property and equipment in accounts payable
operating income of minority interest investment
due from related party																							9,000	9,000	54,000	-8,000
security deposit on sublease																							0
security deposit received from expired lease
proceeds from sale of minority interest investment in former subsidiary																							0
supplemental disclosure of non-cash investing information
operating income on minority interest investment																								123,000	165,000	190,000
purchases of property and equipment with capital lease obligation
financing costs in accounts payable and accrued liabilities
income from discontinued operations																											-130,000	-427,000	-423,000	-514,000	-544,575	-1,679,000
income from continuing operations																							-14,625,000	889,000	-10,008,000	-7,030,000	393,000	-1,779,000	-7,214,000	-3,241,000	-4,480,850	-2,107,000
adjustments to reconcile net income from continuing operations to net cash from operating activities:
gain on deconsolidation of former subsidiary
net cash from continuing operating activities																							-5,076,000	-4,719,000	-3,893,000	-3,687,000	-3,548,000	-2,273,000	-2,468,000	-2,033,000	-2,277,768	-1,122,000
net cash from discontinued operating activities																											-188,000	-404,000	-282,000	-487,000		-1,149,000
net cash from continuing investing activities																							103,000	441,000	-6,000	-10,000	-2,000	-5,000			15,002	-350,000
net cash from discontinued investing activities																															224,780	721,000
net cash from continuing financing activities																														-112,000	13,944,687	0
net cash from discontinued financing activities																											0	700,000	425,000	400,000
net increase in cash and cash equivalents from continuing operations
net decrease in cash and cash equivalents from discontinued operations
supplemental disclosures of non-cash investing and financing information
accrued liability for cost of issuing common stock
warrants issued in connection with sale of common stock
board fees paid with common stock																								0	45,000	46,000	78,000	61,000	54,000	82,000	82,786	82,000	68,000	45,000
accrued compensation and other liabilities
net decrease in cash, cash equivalents and restricted cash from continuing operations																								-4,278,000	-3,899,000	-3,697,000
net increase in cash, cash equivalents and restricted cash from discontinued operations																												296,000
net decrease in cash, cash equivalents and restricted cash																								-4,278,000	-3,899,000	-3,697,000
net increase in cash and cash equivalents included in current assets held for sale																												-372,000	-94,000	-2,000
cash, cash equivalents and restricted cash, beginning of period																								0	0	23,099,000	0	0	0	17,135,000
cash, cash equivalents and restricted cash, end of period																								-4,278,000	-3,899,000	19,402,000	12,860,000	-2,354,000	-2,308,000	14,901,000
accrued compensation and other current liabilities																									123,000	49,000	-210,000	278,000	141,000	-252,000	-4,303	119,000	-239,000	46,000	255,808	-30,000	-372,000	-317,000
net decrease in cash, cash equivalents and restricted cash from discontinued operations																														-87,000
cash paid for the issuance of common stock and common stock warrants
income tax benefit
non-cash expense of issuing shares to aspire capital																																0	0	602,000
other long-term liabilities																															-20,040	0	17,000	-37,000	-40,365	-12,000	-8,000	72,000
costs of essentialis acquisition paid																																-350,000
proceeds from issuance of common stock																															0	0	0	10,000,000
proceeds from sale of common stock and common stock warrants
net increase in cash, cash equivalents and restricted cash from continuing operations																											12,752,000	-2,278,000	-2,357,000	-2,145,000
net increase in cash, cash equivalents and restricted cash																											12,392,000	-1,982,000	-2,214,000	-2,232,000
issuance of common stock in essentialis acquisition																																0	-22,000	18,786,000
contingent consideration of essentialis acquisition																																0	0	1,090,000
net cash from (used) in investing activities
costs of essentialis acquisition included in accounts payable
cash paid for the issuance cost of common stock and common stock warrants																														-112,000
contingent cash consideration of essentialis acquisition
costs of issuing common stock and common stock warrants recorded in accounts payable																														91,000
loss on disposition of equipment
inducement charge for series c warrants																																							-625	0	0	3,050,000
noncash expense of issuing shares to aspire capital
prepaid expenses and other assets																															-197,356	100,000	16,000	-15,000	-28,928	-60,000	59,000	-49,000	57,630	86,000	-52,000	-7,000	-66,123
net cash from discontinued operations
costs of essentialis acquisition
purchase of property and equipment																															1,431	0	0	-4,000	320	0	-20,000	-19,000	-7,777	-32,000	-15,000	-1,000
cash paid for the cost issuance of common stock and common stock warrants
proceeds from exercise of common stock options																																			102	0			-427	0	282,000	12,000
net proceeds from issuance of series a convertible preferred
net proceeds from issuance of series b convertible preferred
redemption of series a convertible preferred stock in conjunction with issuance of series b convertible preferred stock
series a convertible preferred transaction costs paid
net increase in cash and equivalents
supplemental disclosure of cash flow information
cash paid for income taxes
supplemental disclosures of noncash investing and financing information
issuance of common stock for essentialis acquisition
conversion of series a preferred to common stock																																			-1,020,000	0	555,000	1,665,000
conversion of series b preferred to common stock																																		6,000
series b preferred convertible stock transaction costs included in accounts payable
fixed asset purchases included in accounts payable
de-recognition of series b warrant liability through cashless exercise
loss on disposition of property & equipment
proceeds from sale of series a preferred convertible stock																																				0	0	5,071,000
series a preferred convertible stock transaction costs paid																																				0	0	-71,000
proceeds from sale of series b preferred stock
redemption of series a preferred stock in conjunction with issuance of series b preferred stock
continuing operations																																-1,471,000
discontinued operations																																-429,000
de-recognition of series b warrant liability																																								-1,000	0	6,748,000
series b preferred transactions costs in accounts payable
fixed asset purchases in accounts payable
costs of essentialis acquistions included in accounts payable																																		572,000
benefit from deferred taxes
acquisition of neoforce assets
acquisition of bddi asset
increase in restricted cash																																							76,000	-76,000
proceeds from exercise of series a warrants																																							0	0	0	156,000
proceeds from exercise of series b warrants																																							-111,287	0	0	3,832,000
proceeds from issuance of common stock to aspire capital
repayment of credit line																																							471	0	0	-102,000
initial public offering costs paid																																							-45,181	0	0	-530,000
series a preferred convertible stock transaction costs included in accounts payable
de-recognition of series b warrant liability through cash exercise
de-recognition of series a warrant liability through cash exercise
bddi patent purchase consideration included in accrued liabilities
shares issued as consideration for bddi patent purchase
cashless exercise of 2010 and 2012 warrants
contribution of series b warrants
loss on disposition of property and equipment																																				0							-273
cash paid for purchase of assets of neoforce group, inc.
cash paid for patent acquisition
proceeds from sale of series b preferred convertible stock
redemption of series a preferred convertible stock in conjunction with issuance of series b convertible preferred
proceeds from other exercise of series b warrants																																								0	0	189,000
series b warrant transaction costs paid																																								-131,000	0	-175,000
patent costs included in accrued liabilities																																								-150,000
stock issuable in consideration for patent purchase
de-recognition of series a warrant liability																																								0	0	42,000
reduction in initial public offering costs payable																																								0	0	45,000
cashless exercise of 2010/2012 warrants																																								0	0	13,000
de-recognition of series b warrants contributed back to the company																																								0	0	3,000
series b transaction costs in accounts payable
series b warrant transaction costs included in accounts payable
fixed asset costs included in accounts payable																																						11,000
series b warrant transaction costs accrued and included in accrued compensation and other current liabilities																																										131,000
non-cash interest expense relating to convertible promissory notes & amortization of discount on notes
non-cash interest expense relating to line of credit
other receivables
accrued compensation & other current liabilities
proceeds from issuance of series a convertible preferred
proceeds from issuance of preferred stock warrants
proceeds from issuance of convertible notes payable																																											493,781
proceeds from line of credit
proceeds from initial public offering
initial public offering costs accrued and included in accounts payable
beneficial conversion feature related to the warrants to purchase shares of convertible preferred stock in connection with convertible promissory notes
issuance of warrants for the purchase of convertible preferred stock in connection with notes payable
2014 notes payable converted into units in the ipo
2010/2012 notes payable converted into common stock in conjunction with ipo
amortization of intangible assets
change in fair value of preferred stock warrants
non-cash interest expense relating to warrants and convertible promissory notes
inventories																																								-98,000	-72,000	-97,000
accrued liabilities																																								103,000	502,000	115,000
issuance of 50,000 shares of common stock as consideration for patent acquisition
proceeds from sale of property and equipment
issuance of restricted common stock in exchange for intellectual property
proceeds from issuance of warrants
deferred offering costs paid
issuance of warrants in connection with notes payable
beneficial conversion feature in connection with convertible promissory notes
deferred offering costs accrued and included in accounts payable

We provide you with 20 years of cash flow statements for Soleno Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Soleno Therapeutics stock. Explore the full financial landscape of Soleno Therapeutics stock with our expertly curated income statements.

The information provided in this report about Soleno Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.